Preparation and evaluation of naringenin-loaded sulfobutylether-β-cyclodextrin/chitosan nanoparticles for ocular drug delivery.
The aim of this study was to prepare and characterize the naringenin-loaded sulfobutylether-β-cyclodextrin/chitosan nanoparticles (Nag-CD/CS-NPs) and evaluate their potential for the topical ophthalmic delivery. Naringenin was first complexed with sulfobutylether-β-cyclodextrin (SBE-β-CD), which can significantly enhance the solubility of poorly soluble drugs. Then, nanoparticles were prepared by ionic gelation of chitosan with SBE-β-CD, and their in vitro and vivo properties were investigated, respectively. The resulting nanoparticles showed an average size of 446.4±112.8nm and zeta potential of +22.5±4.91mV with predominant spherical in shape. The FT-IR and DSC confirmed the formation of Nag-CD/CS-NPs. The in vitro release study indicated that Nag-CD/CS-NPs achieved moderate sustained-release effect, and the in vivo study revealed that the prepared nanoparticles was nonirritating to rabbit's eye and had better ability to prolong the residence time than the naringenin suspension, which can significantly increase naringenin bioavailability in the aqueous humor. In conclusion, the developed CD/CS nanoparticles offer a potential alternative for the ocular administration of poorly soluble drugs.
Chongqing Research Center for Pharmaceutical Engineering, School of Pharmacy, Chongqing Medical University, Chongqing 400016, PR China.
Ping
P
Zhang
Chongqing Research Center for Pharmaceutical Engineering, School of Pharmacy, Chongqing Medical University, Chongqing 400016, PR China.
Xin
X
Liu
Chongqingshi Shapingba District People's Hospital, Chongqing 400030, PR China.
Wenjing
W
Hu
Chongqing Research Center for Pharmaceutical Engineering, School of Pharmacy, Chongqing Medical University, Chongqing 400016, PR China.
Yan
Y
Bai
Chongqing Research Center for Pharmaceutical Engineering, School of Pharmacy, Chongqing Medical University, Chongqing 400016, PR China. Electronic address: zlkdyx@126.com.
Liangke
L
Zhang
D000287:Administration, Topical; D000818:Animals; D048271:Chitosan / Q000737:chemistry*; D004337:Drug Carriers / Q000737:chemistry*; D065546:Drug Liberation; D005260:Female; D044950:Flavanones / Q000008:administration & dosage / Q000737:chemistry* / Q000627:therapeutic use; D008268:Macular Degeneration / Q000188:drug therapy; D008297:Male; D053758:Nanoparticles / Q000737:chemistry*; D010316:Particle Size; D011817:Rabbits; D012995:Solubility; D047392:beta-Cyclodextrins / Q000737:chemistry*
D004337:Drug Carriers; D044950:Flavanones; D047392:beta-Cyclodextrins; C093196:SBE4-beta-cyclodextrin; D048271:Chitosan; C005273:naringenin
Chitosan nanoparticles; Naringenin; Ocular drug delivery